{
     "PMID": "26456350",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20161005",
     "LR": "20161230",
     "IS": "1873-7064 (Electronic) 0028-3908 (Linking)",
     "VI": "101",
     "DP": "2016 Feb",
     "TI": "Blockade of T-type calcium channels prevents tonic-clonic seizures in a maximal electroshock seizure model.",
     "PG": "320-9",
     "LID": "10.1016/j.neuropharm.2015.09.032 [doi] S0028-3908(15)30124-6 [pii]",
     "AB": "T-type (Cav3) calcium channels play important roles in neuronal excitability, both in normal and pathological activities of the brain. In particular, they contribute to hyper-excitability disorders such as epilepsy. Here we have characterized the anticonvulsant properties of TTA-A2, a selective T-type channel blocker, in mouse. Using the maximal electroshock seizure (MES) as a model of tonic-clonic generalized seizures, we report that mice treated with TTA-A2 (0.3 mg/kg and higher doses) were significantly protected against tonic seizures. Although no major change in Local Field Potential (LFP) pattern was observed during the MES seizure, analysis of the late post-ictal period revealed a significant increase in the delta frequency power in animals treated with TTA-A2. Similar results were obtained for Cav3.1-/- mice, which were less prone to develop tonic seizures in the MES test, but not for Cav3.2-/- mice. Analysis of extracellular signal-regulated kinase 1/2 (ERK) phosphorylation and c-Fos expression revealed a rapid and elevated neuronal activation in the hippocampus following MES clonic seizures, which was unchanged in TTA-A2 treated animals. Overall, our data indicate that TTA-A2 is a potent anticonvulsant and that the Cav3.1 isoform plays a prominent role in mediating TTA-A2 tonic seizure protection.",
     "CI": [
          "Copyright (c) 2015. Published by Elsevier Ltd."
     ],
     "FAU": [
          "Sakkaki, Sophie",
          "Gangarossa, Giuseppe",
          "Lerat, Benoit",
          "Francon, Dominique",
          "Forichon, Luc",
          "Chemin, Jean",
          "Valjent, Emmanuel",
          "Lerner-Natoli, Mireille",
          "Lory, Philippe"
     ],
     "AU": [
          "Sakkaki S",
          "Gangarossa G",
          "Lerat B",
          "Francon D",
          "Forichon L",
          "Chemin J",
          "Valjent E",
          "Lerner-Natoli M",
          "Lory P"
     ],
     "AD": "Universite de Montpellier, CNRS UMR 5203, Departement Neuroscience & Ion Channel Biology, Institut de Genomique Fonctionnelle, Montpellier F-34094, France; INSERM U1191, Montpellier F34094, France; LabEx 'Ion Channel Science and Therapeutics', Montpellier F34094, France; Sanofi R&D, F-91385 Chilly-Mazarin, France. Universite de Montpellier, CNRS UMR 5203, Departement Neuroscience & Ion Channel Biology, Institut de Genomique Fonctionnelle, Montpellier F-34094, France; INSERM U1191, Montpellier F34094, France. Universite de Montpellier, CNRS UMR 5203, Departement Neuroscience & Ion Channel Biology, Institut de Genomique Fonctionnelle, Montpellier F-34094, France; INSERM U1191, Montpellier F34094, France. Sanofi R&D, F-91385 Chilly-Mazarin, France. Universite de Montpellier, CNRS UMR 5203, Departement Neuroscience & Ion Channel Biology, Institut de Genomique Fonctionnelle, Montpellier F-34094, France; INSERM U1191, Montpellier F34094, France. Universite de Montpellier, CNRS UMR 5203, Departement Neuroscience & Ion Channel Biology, Institut de Genomique Fonctionnelle, Montpellier F-34094, France; INSERM U1191, Montpellier F34094, France; LabEx 'Ion Channel Science and Therapeutics', Montpellier F34094, France. Universite de Montpellier, CNRS UMR 5203, Departement Neuroscience & Ion Channel Biology, Institut de Genomique Fonctionnelle, Montpellier F-34094, France; INSERM U1191, Montpellier F34094, France. Universite de Montpellier, CNRS UMR 5203, Departement Neuroscience & Ion Channel Biology, Institut de Genomique Fonctionnelle, Montpellier F-34094, France; INSERM U1191, Montpellier F34094, France. Universite de Montpellier, CNRS UMR 5203, Departement Neuroscience & Ion Channel Biology, Institut de Genomique Fonctionnelle, Montpellier F-34094, France; INSERM U1191, Montpellier F34094, France; LabEx 'Ion Channel Science and Therapeutics', Montpellier F34094, France. Electronic address: philippe.lory@igf.cnrs.fr.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article"
     ],
     "DEP": "20151009",
     "PL": "England",
     "TA": "Neuropharmacology",
     "JT": "Neuropharmacology",
     "JID": "0236217",
     "RN": [
          "0",
          "(2-(4-cyclopropylphenyl)-N-(1-(5-((2,2,2-trifluoroethyl)oxo)pyridin-2-yl)ethyl)ac",
          "etamide)",
          "0 (Benzeneacetamides)",
          "0 (Cacna1g protein, mouse)",
          "0 (Cacna1h protein, mouse)",
          "0 (Calcium Channel Blockers)",
          "0 (Calcium Channels, T-Type)",
          "0 (Convulsants)",
          "0 (Pyridines)",
          "EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)",
          "WM5Z385K7T (Pentylenetetrazole)"
     ],
     "SB": "IM",
     "MH": [
          "Analysis of Variance",
          "Animals",
          "Benzeneacetamides/*therapeutic use",
          "Brain/drug effects/metabolism",
          "Calcium Channel Blockers/*therapeutic use",
          "Calcium Channels, T-Type/genetics/*metabolism",
          "Convulsants/toxicity",
          "Disease Models, Animal",
          "Dose-Response Relationship, Drug",
          "Electroshock/adverse effects",
          "Evoked Potentials/drug effects/genetics",
          "Extracellular Signal-Regulated MAP Kinases/metabolism",
          "Male",
          "Mice",
          "Mice, Inbred C57BL",
          "Mice, Knockout",
          "Pentylenetetrazole/toxicity",
          "Pyridines/*therapeutic use",
          "Seizures/etiology/pathology/*prevention & control"
     ],
     "OTO": [
          "NOTNLM"
     ],
     "OT": [
          "Anticonvulsant",
          "Local Field Potential",
          "Maximal electroshock seizure",
          "T-type voltage-gated calcium channels",
          "Tonic-clonic seizure"
     ],
     "EDAT": "2015/10/13 06:00",
     "MHDA": "2016/10/07 06:00",
     "CRDT": [
          "2015/10/13 06:00"
     ],
     "PHST": [
          "2015/06/19 00:00 [received]",
          "2015/09/11 00:00 [revised]",
          "2015/09/30 00:00 [accepted]",
          "2015/10/13 06:00 [entrez]",
          "2015/10/13 06:00 [pubmed]",
          "2016/10/07 06:00 [medline]"
     ],
     "AID": [
          "S0028-3908(15)30124-6 [pii]",
          "10.1016/j.neuropharm.2015.09.032 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Neuropharmacology. 2016 Feb;101:320-9. doi: 10.1016/j.neuropharm.2015.09.032. Epub 2015 Oct 9.",
     "term": "hippocampus"
}